



TECH
PAPER 1600/2900
Sheet last 2
88
2000
1600/2900

RECEIVED

Form 1449*

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Atty. Docket No.: 1343.016US1

Serial No. 09/846,892

Applicant: J. Kevin Judice et al.

Filing Date: May 1, 2001

Group: 1600/2900

U. S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>Swl</i>	4,643,987	02/17/1987	Nagarajan et al.	514	8	08/14/85
	4,698,327	10/06/1987	Nagarajan et al.	514	8	04/18/86
	4,727,064	02/23/1988	Pitha	514	58	05/29/85
	4,983,586	01/08/1991	Bodor	514	58	03/29/88
	5,134,127	07/28/1992	Stella et al.	514	058	01/23/90
	5,324,718	06/28/1994	Loftsson	514	58	07/14/92
	5,376,645	12/27/1994	Stella et al.	514	58	07/27/92
	5,472,954	12/05/1995	Loftsson	514	58	05/11/94
	5,591,714	01/07/1997	Nagarajan et al.	514	9	10/13/94
	5,602,112	02/11/1997	Rubinfeld	514	58	08/26/94
	5,750,509	05/12/1998	Malabarba et al.	514	11	04/30/96
	5,804,568	09/08/1998	Rubinfeld	514	58	02/03/97
	5,840,684	11/24/1998	Cooper et al.	514	11	03/24/95
	5,874,418	02/23/1999	Stella et al.	514	58	05/05/97
	5,916,873	06/29/1999	Cooper et al.	514	9	04/01/98
	5,985,310	11/16/1999	Castillo et al.	424	427	08/08/97
	6,046,177	04/04/2000	Stella et al.	514	58	01/13/99
<i>Swl</i>	6,048,845	04/11/2000	Rubinfeld	514	58	08/28/98

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>Swl</i>	00/39156	07/06/2000	PCT	G07K	9/00	
	00/59528	10/12/2000	PCT	A61K	38/08	
	0149197	07/24/1985	European	A61K	9/10	
	0335545	10/04/1989	European	A61K	9/05	
	0667353	08/16/1995	European	G07K	9/00	
	0816378	01/07/1998	European	G07K	9/00	
	1222697	06/09/1987	Canada	A61K	47/00	
	82/00251	02/04/1982	PCT	A61K	31/74	
	94/20136	09/15/1994	PCT	A61K	39/12	
<i>Swl</i>	95/06485	03/09/1995	PCT	A61K	47/48	
	98/55148	12/10/1998	PCT	A61K	47/48	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Document Description
<i>Swl</i>	Allen, N.E., et al., "The Role of Hydrophobic Side Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide Antibiotics", The Journal of Antibiotics, 50 (8), pp. 677-684, (Aug. 1997)

Examiner *Swl*

Substitute Disclosure Statement Form (PTO-1449)

Date Considered *8-27-03*

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

TECH CENTER 1
 NOV 8 2001
 SPect 2002
 1000/2000

Form 1449*	Atty. Docket No.: 1343.016US1	Serial No. 09/846,893
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: J. Kevin Judice et al.	Filing Date: May 1, 2001
		Group: 161

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial

<u>Swl</u>	Ge, M., et al., "Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding", <u>Science</u> , 284, pp. 507-511, (April 16, 1999)
<u>Swl</u>	Nagarajan, R., et al., "Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins", <u>The Journal of Antibiotics</u> , XLIII (1), pp. 63-72, (Jan. 1989)
<u>Swl</u>	Nicolaou, K.C., et al., "Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics", <u>Angew. Chem. Int. Ed.</u> , 38, pp. 2097-2152, (1999)
<u>Swl</u>	Pavlov, A.Y., et al., "A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity", <u>The Journal of Antibiotics</u> , 50 (6), pp. 509-513, (June 1997)
<u>Swl</u>	Pavlov, A.Y., et al., "Chemical Modification of Glycopeptide Antibiotics [VC1]", <u>Russian Journal Of Bioorganic Chemistry</u> , 24 (9), pp. 570-587, (1998)
<u>Swl</u>	Pavlov, A.Y., et al., "Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7; Structure-activity Relationship", <u>The Journal of Antibiotics</u> , 51 (1), pp. 73-78, (Jan. 1998)
<u>Swl</u>	Zhang, M., et al., "A review of recent applications of cyclodextrins for drug discovery", <u>Expert Opinion on Therapeutic Patents</u> , 9 (12), 21 p., (1999)

Examiner

Date Considered

Substitute Disclosure Statement Form (PTO-1449)

8-27-03

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


PTO/SB/04 (10-01)
Approved for use through 10/31/2002. OMB 651-0031
U.S. Patent & Trademark Office DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known	
Application Number	09/846893
Filing Date	May 1, 2001
First Named Inventor	Judice, J.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No: 01343.016US1	

Sheet 1 of 1

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
SWL	WO-00/54751	09/21/2000	Berndt, Gunther , et al			
	WO-01/83520	11/08/2001	Linsell, Martin S., et al			
	WO-01/97851	03/13/2002	Choi, Seung-Ho , et al			
	WO-01/98326	12/27/2001	Mu, YongQi			
	WO-01/98327	12/27/2001	Linsell, Martin , et al			
	WO-01/98328	12/27/2001	Leadbetter, M.R., et al			
	WO-01/98329	12/27/2001	Yang, Guang , et al			
SWL	WO-94/12217	06/09/1994	Tsao, Sheng-Wan , et al			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

EXAMINER

Samko

DATE CONSIDERED

8-27-03

Substitute Disclosure Statement Form (PTO-1440)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Drawing through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

06/08/2004 12:35 FAX 650 808 6078

THERAVANCE PATENT


020

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

Sheet 1 of 1



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Atty. Docket No.: 1343.016US1

Serial No. 09/846,893

Applicant: J. Kevin Judice et al.

Filing Date: May 1, 2001

Group: 1614

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>swl</i>	5,024,998	06/18/1991	Bodor, N.S.	514	58	12/11/89

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial

Examiner

Sam J. Judice

Date Considered

8-17-03

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.